C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 314—Applications for Fda Approval to Market A New DrugSubpart D—Fda Action on Applications and Abbreviated Applications

21 C.F.R. § 314.100 (2026)

Timeframes for reviewing applications and abbreviated applications

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1979–2020 8citing cases
At a glance

Courts have cited this section in 8 opinions since 1979.

(a) Except as provided in paragraph (c) of this section, within 180 days of receipt of an application for a new drug under section 505(b) of the act or an abbreviated application for a new drug under section 505(j) of the act, FDA will review it and send the applicant either an approval letter under § 314.105 or a complete response letter under § 314.110. This 180-day period is called the “initial review cycle.”

(b) At any time before approval, an applicant may withdraw an application under § 314.65 or an abbreviated application under § 314.99 and later submit it again for consideration.

(c) The initial review cycle may be adjusted by mutual agreement between FDA and an applicant or as provided in §§ 314.60 and 314.96, as the result of a major amendment.

[73 FR 39609, July 10, 2008]
The 8 cases that cite 21 C.F.R. § 314.100 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENParke, Davis & Co. v. Joseph A. Califano, 623 F.2d 1 (6th Cir. 1980).
cites § 314.100 1×cited by 39 cases
Where it cites § 314.100
“21 C.F.R. §§ 314.100 et seq. In addition to requiring approval if none of the grounds specified in 21 U.”
The case’s holding
An agency invoking the FOIA deliberative process privilege must show how each withheld document fits into the decision-making process, rather than relying on conclusory affidavits of exemption.
Later courts cite it for
“the district court must know how each document fits into the deliberative process, and whether it is an essential element of that process or possibly a peripheral item which just 'beefs up' a position with cumulative materials.” · 3 citing courts
2
GREENTummino v. Torti, 603 F. Supp. 2d 519 (E.D.N.Y. 2009).
cites § 314.100 1×cited by 15 cases
Where it cites § 314.100
“§ 355 (c); 21 C.F.R. § 314.100 (a). Moreover, during this seven month period— during which time no FDA staff appear to have worked on the Plan B matter — neither Acting Deputy Commissioner Woodcock nor Acting CDER Director Galson knew what Acting Commissioner Crawford was doing…”
The case’s holding
An agency decision is arbitrary and capricious under the Administrative Procedure Act if it results from political interference, bad faith, or departures from normal procedures without reasoned explanation.
Later courts cite it for
“trusted to conduct a fair assessment of the scientific evidence.” · 2 citing courts
3
GREENTorPharm, Inc. v. Thompson, 260 F. Supp. 2d 69 (D.D.C. 2003).
cites § 314.100 1×cited by 15 cases
Where it cites § 314.100
“20 (e) (general rule for FDA docket submissions); 21 C.F.R. § 314.100 (a) (timeframes for reviewing NDAs and ANDAs); 314 C.”
Later courts cite it for
“either the applicant is seeking approval for the use claimed in the patent, or it is not.” · 2 citing courts
4
GREENBristol-Myers Squibb Co. v. Copley Pharm., Inc., 144 F. Supp. 2d 21 (D. Mass. 2000).
cites § 314.100 1×cited by 10 cases
Where it cites § 314.100
“§ 355 (j)(5)(A); 21 C.F.R. § 314.100 . Copley may receive tentative approval of the ANDA, with only final approval delayed by the litigation.”
5
GREENNorwich Eaton Pharm., Inc. v. Bowen, 808 F.2d 486 (6th Cir. 1987).
cites § 314.100 2×cited by 14 cases
Where it cites § 314.100
“The District Court thus concluded that the FDA’s letter of December 29, 1981 merely indicated Buprenex’s “approvable” status under 21 C.F.R. § 314.100 (d) 3 and that “the FDA’s ‘approval’ of the Buprenex NDA was contingent upon and not effective until approval of labeling in its…”
Later courts cite it for
“consideration of evidence outside the administrative record is proper under some circumstances, e.g., 'for background information . . . or for the limited purposes of ascertaining whether the agency considered all the relevant factors or fully explicated its course of conduct or grounds of decision.” · 3 citing courts
6
GREENPharm. Mfrs. Ass'n v. Kennedy, 471 F. Supp. 1224 (D. Md. 1979).
cites § 314.100 1×cited by 8 cases
Where it cites § 314.100
“Omission of a drug product from the list would not necessarily mean that the drug product is in violation of section 505 and 507 of the act, or that it is not safe or effective, or that it may not be therapeutically equivalent to other drug products. Decisions on whether…”
7
REDNorwich Eaton Pharm., Inc. v. Bowen, 645 F. Supp. 321 (S.D. Ohio 1986).
cites § 314.100 1×cited by 2 cases
Reversed by Norwich Eaton Pharmaceuticals, Inc. v. Bowen (1987): the Court of Appeals for the Sixth Circuit's own opinion in this case.
Where it cites § 314.100
“Finkel was notice of the “approvable” status of Buprenex in accordance with the FDA’s ordinary practice under 21 C.F.R. § 314.100 (d). It is equally clear that Dr.”
8
NEUTRALTomaszewski v. Trevena, Inc., 482 F. Supp. 3d 317 (E.D. Pa. 2020).
cites § 314.100 1×cited by 0 casesunknown
Where it cites § 314.100
“81 Because conclusory allegations do not satisfy the PSLRA’s heightened standards, Plaintiffs’ cannot maintain a claim based on Soergel’s July 20, 2017 statement.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
197919992020

One bar per year. Tallest: 1 case in 1979. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
6th Cir.2D.D.C.1D. Mass.1D. Md.1E.D.N.Y1S.D. Ohio1E.D. Pa.1
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com